Mario Perro, PhD

Head of Biologics Research & Site Head, SVP at Ichnos Glenmark Innovation

Speaker

Mario Perro has worked in the field of oncology and cancer immunology since 2006. First focusing on Adoptive T cell transfer for the treatment of Acute Myeloid Leukaemia (AML), in 2015 Mario redirected his studies in the development of bispecific checkpoints and T cell engagers at Roche. Among many drug molecules evaluated, Mario contributed to the characterisation of Glofitamab and the development of Artificial Intelligence approach to investigate Tumour Microenvironment modification induced by a CEA targeted TCE in combination of check point inhibitors . At present, Mario is heading the Oncology Research Department at Ichnos Sciences, focusing on next generation multispecific antibodies such as ISB 1442, a CD38xCD47 macrophage engager, and ISB 2001, a BCMAxCD38xCD3 T cell engager.